FIELD: biotechnology.
SUBSTANCE: invention relates to variants of an engineered CRISPR-Cas system containing a fusion protein containing the Cas9 protein fused to at least one nuclear localization signal (NLS), or one or more nucleic acid molecules encoding this fusion protein, and CRISPR-Cas RNA or one or more nucleic acid molecules encoding CRISPR-Cas RNA.
EFFECT: invention is effective for modifying a eukaryotic cell.
44 cl, 74 dwg, 15 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796017C2 |
| NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND USE IN THERAPY | 2013 |
|
RU2721275C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| RNA-GUIDED TRANSCRIPTION REGULATION | 2014 |
|
RU2756865C2 |
| CRISPR/CAS9 TYPE II GENOME EDITING SYSTEM AND ITS USE | 2022 |
|
RU2794774C1 |
| DNA-CUTTING AGENT BASED ON THE Cas9 PROTEIN FROM THE BACTERIUM CAPNOCYTOPHAGA OCHRACEA | 2021 |
|
RU2778156C1 |
